Relationship between myocardial viability and improvement in left ventricular function and heart failure symptoms

I Peovska1, J Maksimovic, M Vavlukis

  • 1Heart Diseases Institute, Clinical Centre, Skopje, R. Macedonia. irenapeovska@yahoo.com

Prilozi
|October 9, 2007
PubMed

Insights

Assessing myocardial viability before coronary artery bypass surgery (CABG) predicts improved left ventricular (LV) function and heart failure symptom relief. Substantial viability indicates better outcomes after revascularization.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Cardiac Surgery

Background:

  • Myocardial viability assessment is crucial for predicting outcomes after coronary artery bypass surgery (CABG).
  • The association between myocardial viability and heart failure symptom improvement post-revascularization requires further clarification.

Purpose of the Study:

  • To establish the relationship between the extent of viable myocardium and left ventricular (LV) function improvement post-CABG.
  • To determine if preoperative viability testing predicts heart failure symptom improvement after revascularization.

Main Methods:

  • Eighty-five patients with ischemic cardiomyopathy underwent Tc-99m sestamibi myocardial perfusion SPECT (MPI) for viability assessment.
  • LV function and heart failure symptoms (NYHA criteria) were evaluated pre- and post-revascularization (16 ± 6 months).
  • Quantitative analysis used a 17-segment LV model and Bull's eye plots for MPI.

Main Results:

  • A direct correlation (r=0.79, P<0.01) was found between the number of viable segments and LV ejection fraction (LVEF) improvement.
  • Four or more viable segments (≥24% of LV) predicted LVEF improvement with 83% sensitivity and 79% specificity.
  • Presence of ≥4 viable segments predicted heart failure symptom improvement (PPV 79%, NPV 74%).

Conclusions:

  • Substantial myocardial viability (≥4 segments, 24% LV) on gated SPECT MPI strongly correlates with improved LVEF and heart failure symptoms post-CABG.
  • Preoperative viability assessment is valuable for predicting functional recovery and symptom relief in patients undergoing revascularization for ischemic heart failure.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...